Axena is a commercial-stage women’s health company offering the Leva Pelvic Health System, a device for managing urinary incontinence.

Axena has developed Leva, a clinically validated, home-based pelvic floor therapy platform that delivers scalable, supervised first-line incontinence care. By leveraging an Intravaginal motion-sensing accelerometer with real-time biofeedback and cloud-based clinician monitoring, Axena is moving first-line UI care from episodic clinic-based therapy to continuous, supervised, home-based care at scale. Patients gain access to evidence-based, first-line treatment with high adherence, meaningful symptom reduction, lower barriers to care, and broader insurance coverage reducing out-of-pocket costs. Prescribers and payers benefit from measurable outcomes, lower need for costly procedures, improved access, and reimbursement pathways that align economic incentives with guideline-directed first-line therapy.